Quest PharmaTech Inc. Quest is pleased to announce that patient enrollment has been completed in the Phase I clinical study of SL017 Topical Gel for the photodynamic therapy of actinic keratosis , with centers in Edmonton and Montreal.
From: biz.yahoo.com
Quest PharmaTech Completes the Enrollment of Patients in Phase I Clinical Study of SL017 Topical Gel for Photodynamic ...
Posted by Ruslan Abuzant at 8:32 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment